Altamira Therapeutics (CYTO): Price-to-Projected Revenue Ratio
Altamira Therapeutics (CYTO) minimizes early-stage risks through the licensing of IT solutions and the sale of retail goods. The historical forward P/S allows for an assessment of market expectations, where the value of 4.40 reflects this status. Prospects are bolstered by robotic particle synthesis to accelerate prototyping, while the pristine condition of cleanroom equipment guarantees no downtime in RNA research.
Summary analytical data breakdowns for altamiratherapeutics.com (CYTO)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Equity Altamira Therapeutics|CYTO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Altamira Therapeutics Ltd.|CYTO - Company Total Debt Obligations|Debt to Book Capitalization Ratio Altamira Therapeutics|CYTO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Altamira Therapeutics|Quick Liquidity Indicator altamiratherapeutics.com
- net income and valuation multiples indicators:
CYTO - Final Profit|Future Profit Altamira Therapeutics|CYTO - Market Price to Net Income Ratio|Forward P/E Multiple Altamira Therapeutics Ltd.|CYTO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Altamira Therapeutics|CYTO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Altamira Therapeutics|CYTO - Earnings per share for the trailing year|Quarterly EPS earnings growth altamiratherapeutics.com|CYTO - Earnings growth in current year|Net earnings per share growth forecast for next year Altamira Therapeutics
- issuer revenue and sales details:
Comprehensive company analysis:CYTO (Auris Medical)
For Altamira Therapeutics (CYTO), which implements robotic screening and software automation for RNA therapy data, the forward P/S ratio compares the current market value of the business with projected annual sales. This chart allows for an assessment of the extent to which assets are overvalued relative to expected cash flow, where sharp deviations in the forward P/S trend signal speculative pressure or a fundamental reassessment of the company's stability.
Key competitors
Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|VRNA - Price-to-Projected Revenue Ratio|MENS: Price-to-Projected Revenue Ratio|LGND (Ligand Pharmaceuticals) - Forward Price-to-Revenue Multiple|AMRX: Price to Expected Revenue Ratio|PRGO (Perrigo) - Forward P/S Multiple|Forward P/S Multiple Alvotech S.A.|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|Forward Price-to-Revenue Multiple Galapagos Corp GLPG|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Market Cap to Expected Sales Ratio mannkindcorp.com (MNKD)|AMPH - Price-to-Projected Revenue Ratio|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|SPRY: Forward P/S Multiple|Theravance Corp (TBPH) - Forward P/S Multiple|Forward Price-to-Revenue Multiple AQST|SCPH: Forward Price to Sales|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|Price to Expected Revenue Ratio TNXP|Forward P/S Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Forward Price to Sales EPRX|BioHarvest Sciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio invizyne.com|oramed.com (ORMP) - Price-to-Projected Revenue Ratio|Entera Bio - Forward Price to Sales|HYFT (MindWalk) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma, Inc|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|QNTM: Future Price to Revenue|Forward P/S Multiple FGEN (FibroGen)|Telomir Pharmaceuticals Inc (TELO) - Market Cap to Future Revenue Ratio|RANI: Forward Price-to-Revenue Multiple|SNYR - Forward P/S Multiple|RLYB (rallybio.com) - Forward Price-to-Revenue Multiple|LEXX: Price to Expected Revenue Ratio|PULM (Pulmatrix) - Forward P/S Multiple|Pheton (PTHL) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APM|Forward Price-to-Revenue Multiple Lyra Therapeutics Inc LYRA|Price-to-Projected Revenue Ratio Impact BioMedical Inc IBO|Market Cap to Expected Sales Ratio TNF Pharmaceuticals Inc. (TNFA)|cbdMD Corp - Forward P/S Multiple|PainReform Ltd (PRFX) - Forward Price-to-Revenue Multiple|LIPO (Lipella) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Forward Price-to-Revenue Multiple PIRS|PROC (procapsgroup.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|QLI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Revenue
